Enigma Biomedical USA Assembles Global Scientific Dream Team to Tackle Neurodegenerative Diseases
Knoxville, Tennessee – In a move to accelerate the fight against devastating neurodegenerative conditions like Alzheimer’s, Enigma Biomedical USA (EB USA) today announced the formation of a powerhouse Scientific Advisory Board (SAB). Composed of internationally recognized physicians and scientists, this team boasts expertise spanning the spectrum from fundamental chemistry and biology to the cutting edge of medical treatment for these complex diseases.
"We are thrilled to assemble such a remarkably accomplished advisory board, and I am honored to serve as its chairperson," said Professor Serge Gauthier, CM, C.Q, M.D., FRCPC, renowned neurologist from McGill University, Montreal. "We have a unique mix of complementary expertise from basic sciences to clinical practice that will accelerate knowledge transfer and help persons living with neurodegenerative conditions and their care partners,”
Gauthier, a past Director of the McGill University Research Center for Studies in Aging and currently Professor Emeritus in Neurology and Psychiatry at McGill University, will be leading a veritable who’s-who of global experts:
-
Richard Hargreaves, Ph.D., Senior Vice President Head of Neuroscience TRC from Bristol Myers Squibb, New Jersey.
-
Kenji Ishii, M.D., Leader of the Team for Neuroimaging Research at the Tokyo Metropolitan Institute of Gerontology, Japan
-
Keith Johnson, M.D., Ph.D., Director of Molecular Neuroimaging at Massachusetts General Hospital and Neurologist at the Memory Disorders Unit of Brigham and Women’s Hospital; and Professor of Radiology and Neurology at Harvard Medical School, Massachusetts.
-
Sterling Johnson, Ph.D., the Jean R. Finley Professor of Geriatrics and Dementia in the Department of Medicine, Division of Geriatrics and Gerontology at the University of Wisconsin, Madison, and Principal Investigator of the Wisconsin Registry for Alzheimer’s Prevention (WRAP).
-
Eric M. Reiman, M.D., Executive Director of Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona; University Professor of Neuroscience at Arizona State University; Senior Scientist, Translational Genomics Research Institute; and Director, Arizona Alzheimer’s Consortium.
-
Christopher Rowe FRACP, M.D.,Director of Molecular Imaging Research and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Australia
-
Koen Van Laere, M.D., Ph.D., D.Sc., Head of Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium
- Henrik Zetterberg, M.D., Ph.D., Professor/ Chief Physician, Institute for Neuroscience and Physiology, University of Gothenburg, Sweden; Group Leader, UK Dementia Research Institute, University College London, UK; and Visiting Professor at the University of Wisconsin, Wisconsin.
"EBG USA greatly appreciates the commitment of these world-class researchers to work with us to advance our mission," said Rick Hiatt, President and CEO of EB USA.
"We expect this collaboration to yield major strides toward addressing the unmet needs in neurodegenerative disease as well as providing future tools and technologies to support the development of disease modifying therapies,"
This strategic move by EB USA signals a bold step forward in the fight against neurodegenerative diseases. The newly formed SAB promises to leverage its collective knowledge and expertise to accelerate research, develop innovative treatments, and ultimately improve the lives of millions affected by these debilitating conditions.
